China trial speed draws oncology go-East plans
China’s clinical trial advantage is no longer only a conference talking point. Peer-reviewed metrics on registration volume and start-up speed, plus June 2026 NMPA clearances that pull Western ADCs east and advance China-origin CAR-T programs, show why oncology sponsors increasingly treat China as a day-one geography rather than a late rescue region.
Contents11 sections
Key Takeaways
- A 2025 Nature review reports 4,300 China drug clinical trial registrations in 2023 (+26.1%), with oncology dominating Category 1 innovative-drug trials at 40.6%.
- The same review cites 56.3% of new-drug trials starting recruitment within six months in 2023 and a 60-working-day silent-approval CTA mechanism.
- Adcentrx said June 2026 NMPA IND clearance lets it add China sites to STEAP1 ADC study NCT06710379 to accelerate enrollment.
- OriCell said NMPA cleared confirmatory Phase II for GPC3 CAR-T Ori-C101 in late-line HCC after ASCO 2026 Phase I oral data (50% ORR evaluable).
China oncology trial advantage at a glance
| Field | Detail |
|---|---|
| China trial volume 2023 | 4,300 drug clinical trial registrations (+26.1% vs 2022) |
| Innovative-drug focus | 1,606 Category 1 innovative-drug trials; 40.6% oncology |
| Start-up speed | 56.3% start recruitment within 6 months; avg 3.0 months same-year start |
| CTA mechanism cited | 60-working-day silent approval if no objection |
| Western go-East example | Adcentrx ADRX-0405 — NMPA IND; NCT06710379 recruiting |
| China-origin oncology example | OriCell Ori-C101 — NMPA confirmatory Phase II clearance (June 2026) |
| Phase I signal (company) | BEACON ORR 50% evaluable; 66.7% at RP2D; ASCO 2026 oral |
What peer-reviewed data quantify China’s trial machine?
A July 2025 review in Nature’s Signal Transduction and Targeted Therapy maps China’s shift from a generics-heavy market toward innovative drug development. Using ClinicalTrials.gov and other registries, the authors report China had conducted 57,667 trials as of 2023 — 12.7% of global trials — up from 702 trials (3.2%) in 2003.
On domestic registration pace, the review states that in 2023 China for the first time surpassed 4,000 annual drug clinical trial registrations, reaching 4,300, a 26.1% increase versus 2022. New-drug clinical trials were 2,323 (54.0%), and Category 1 innovative-drug trials totaled 1,606, of which oncology accounted for 40.6% (652/1,606).
Journal primary: Nature Signal Transduction and Targeted Therapy — innovative drug development and regulatory support in China.
How fast do China trials actually start recruiting?
Speed, not only volume, is the advantage sponsors cite. The Nature review reports that during 2021–2023, over half of new-drug clinical trials initiated subject recruitment within six months. In 2023 that share was 56.3%, up from 51.4% in 2021.
For trials that began recruitment in the same year as approval, average initiation time fell to 3.0 months in 2023 from 3.3 months in 2022, with 93.4% starting within six months. On the regulatory side, the review describes a 60-working-day “silent approval” mechanism for clinical trial applications: if authorities do not object within that window, the application proceeds by default — a sharp contrast with older multi-year CTA waits.
Those figures are literature-synthesized national statistics, not a guarantee for every oncology protocol. Still, they are the strongest allowlisted quantitative base for a “China is faster” claim.
How are Western biotechs operationalizing a go-East day-one plan?
Adcentrx Therapeutics offers a concrete 2026 example. On 8 June 2026, the San Diego- and Shanghai-based company said China’s National Medical Products Administration cleared an IND for ADRX-0405, a STEAP1-targeted antibody-drug conjugate. The clearance enables China clinical centers to join the ongoing Phase 1a/1b study already initiated in the United States.
CEO Hui Li said the move broadens geographic representation and allows the company to generate data across more diverse populations while addressing unmet needs in metastatic castration-resistant prostate cancer, gastric cancer, and non-small cell lung cancer. The company anticipates completing the Phase 1a portion by the fourth quarter of 2026.
Wire primary: PR Newswire — Adcentrx NMPA IND clearance for ADRX-0405 (8 June 2026).
What does ClinicalTrials.gov show for ADRX-0405?
The registry record NCT06710379 lists the study as recruiting, industry-sponsored by Adcentrx, with estimated enrollment of 68 participants. Start date is 30 December 2024; primary completion is estimated July 2026. Phase 1a is dose escalation in select advanced solid tumors including mCRPC, gastric cancer, and NSCLC; Phase 1b expands in previously treated mCRPC.
Primary objectives are safety, tolerability, pharmacokinetics, and identification of an optimal dose. That registry identity lets readers separate company narrative from protocol facts: China site expansion is an enrollment and diversity strategy layered onto an already public first-in-human design, not a separate China-only pivotal.
Registry primary: ClinicalTrials.gov NCT06710379 — ADRX-0405 in advanced solid tumors.
What China-origin oncology program shows confirmatory momentum?
Go-East is not only inbound Western INDs. On 7 June 2026, OriCell Therapeutics said NMPA cleared Ori-C101, a GPC3-targeted autologous CAR-T, to enter a confirmatory Phase II randomized, open-label, multi-centre registration trial in GPC3-positive advanced hepatocellular carcinoma after two or more prior lines of therapy.
The company said Phase I BEACON results were featured as an ASCO 2026 oral presentation. Reported figures include objective response rate of 50% across the evaluable population, 66.7% in the recommended Phase II dose cohort, and 100% in the highest dose cohort (DL4), with 89% of responders already responding at first post-infusion assessment. The release also cites median overall survival of 21.4 months in the overall population — company-reported Phase I data pending full peer-reviewed publication details in this brief.
Wire primary: PR Newswire — OriCell Ori-C101 NMPA Phase II clearance (7 June 2026).
What remains unproven about the go-East advantage
Keep the claim boundaries tight:
- Nature metrics are national aggregates; they do not prove every ADC or CAR-T protocol will enroll faster in Shanghai than in Boston.
- Adcentrx’s China IND clearance does not yet report China-specific enrollment counts or comparative time-to-first-patient versus U.S. sites.
- OriCell’s ORR and OS figures are company disclosures from Phase I / ASCO presentation context; confirmatory Phase II randomized results are not yet available.
- Secondary trade commentary about “day-one China for every biotech” is not cited here and is not required to explain the verified pattern.
What stands: peer-reviewed China trial-volume and start-up statistics; a June 2026 Western ADC NMPA IND tied to NCT06710379; and a June 2026 China-origin GPC3 CAR-T confirmatory clearance after ASCO 2026 Phase I data.
Related NovaPharma coverage
- Insilico Medicine alliance with Bora Pharmaceuticals
- Leqembi real-world LEADER study at AAIC 2026
- Nektar Therapeutics pipeline update
Frequently Asked Questions
What speed metrics support China’s clinical trial advantage?
A 2025 Nature Signal Transduction and Targeted Therapy review reports China registered 4,300 drug clinical trials in 2023 (+26.1% year over year), with 56.3% of new-drug trials starting recruitment within six months and average same-year recruitment initiation of 3.0 months, alongside a 60-working-day silent-approval CTA mechanism.
How are Western biotechs adding China sites on day one?
In June 2026, Adcentrx said China’s NMPA cleared an IND for STEAP1 ADC ADRX-0405 so the company can add China centers to its ongoing U.S.-initiated Phase 1a/1b study NCT06710379 in late-stage solid tumors, explicitly to broaden geography and accelerate enrollment.
What China-led oncology readout shows local confirmatory speed?
In June 2026, OriCell said NMPA cleared Ori-C101, a GPC3-targeted CAR-T, for a confirmatory Phase II randomized trial in late-line advanced hepatocellular carcinoma after Phase I BEACON data were presented orally at ASCO 2026, including a 50% ORR in the evaluable population.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for ADRX-0405.
Unlock full calendar →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- La Negoziazione del Prezzo dei Farmaci Oncologici in Italia — This whitepaper analyzes the market benchmark role in negotiating oncology drug prices in Italy, hig…
- Cytological Specimens in the Molecular Era of Metastatic Melanoma — This whitepaper discusses the role of cytological specimens in diagnosing metastatic melanoma and th…